Scientific deep-dive

Protein Targets and the Lab Panel

At least 1.2 g of protein per kg daily, 0.3–0.4 g/kg per meal, and a six-test panel: vitamin D, B12, iron studies, folate, zinc, thiamin. The upper protein target excludes chronic kidney disease.

By Nora Bissett · Pricing Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
5 min read·2 citations

“Eat more protein and get your bloods done” is the standard advice, and it is useless without numbers. Two 2026 reviews put numbers to it: a floor of 1.2 g protein for every kilogram you weigh, divided so each meal carries its share, plus a six-test laboratory panel.[1][2] What follows is those figures and the one exclusion attached to them.

The protein targets

Protein targets proposed in a 2026 dietitian-led framework for people on incretin therapy.
TargetAmount
Daily intake≥1.2 g/kg body weight
Upper range, appropriate adults without CKDup to 1.6 g/kg
Per meal~0.3–0.4 g/kg
Leucine per meal~2.5–3 g
The upper target explicitly excludes chronic kidney disease, and that exclusion is not a footnote for this readership. Reduced kidney function is common in the people prescribed these drugs, and higher protein intake is not neutral when it is present. Our kidneys article covers why. If you do not know your kidney function, that is the test to do before raising protein, not after.

The per-meal figure matters more than people expect. Muscle protein synthesis responds to a threshold dose at a sitting rather than to a daily total, which is why the framework specifies both. On a drug that suppresses appetite, hitting a per-meal target across fewer, smaller meals is genuinely hard — and it is the practical reason protein tends to be the macronutrient that slips.

The laboratory panel

The proposed panel is short and specific: vitamin D, B12, iron studies, folate, zinc and thiamin.[1]

Each is there for a reason connected to how these drugs work rather than to general wellness testing. Reduced intake and reduced dietary diversity affect all of them; nausea and vomiting affect thiamin acutely; and baseline inadequacy is already common in people with obesity before any drug is involved, which the reviews note explicitly.[1][2]

What runs low in practice, with figures from a large dataset, is covered separately in eating too little on a GLP-1. This panel is the counterpart: not what falls, but what to measure.

Six tests. It is a short list precisely so that it gets done.

Energy floors

The same framework proposes pragmatic energy floors — a minimum daily intake below which micronutrient adequacy becomes very difficult regardless of what you choose to eat.[1] That is the conceptual point worth taking even without a specific number: below a certain intake, no amount of good food selection compensates, because there is not enough food.

This is where the appetite suppression that makes the drug work becomes the thing to manage. Appetite is a poor guide to adequacy on these drugs by design, which is the argument for eating to a plan rather than to hunger.

What kind of evidence this is

Both sources are narrative reviews proposing a framework, not randomized trials testing one. The protein targets are guideline-informed extrapolations into a new context rather than figures validated in people taking these drugs.

That is a real limitation and it does not make them useless. There is no trial establishing the right protein intake on a GLP-1, and there may never be one; in its absence, an explicit number derived from established nutrition guidance is more useful than “eat more protein”. Our lean mass article covers the outcome these targets are aimed at, and the one intervention with randomized support behind it: resistance training.

Frequently Asked Questions

References

  1. 1.Arslan S, et al. Medical nutrition in the glucagon-like peptide-1 (GLP-1) era: Protein strategies, micronutrient monitoring, and lean mass preservation Clinical Nutrition ESPEN. 2026. PMID: 42036071.
  2. 2.Simancas-Racines D, Campuzano-Donoso M, Rossetti G, et al. Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: Mechanistic pathways, clinical signals, and a monitoring framework Obesity Pillars. 2026. PMID: 42382663.

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.5

Strut Health

Semaglutide at $99/month, 48% under the register median

9.1

Care Bare Rx

Knowing which pharmacy fills the vial — it names Belmar Pharmacy

7.9

Oak

Semaglutide at $119/month, 37% under the register median